150 related articles for article (PubMed ID: 15225699)
1. Preparation of novel aza-1,7-annulated indoles and their conversion to potent indolocarbazole kinase inhibitors.
Al-awar RS; Ray JE; Hecker KA; Joseph S; Huang J; Shih C; Brooks HB; Spencer CD; Watkins SA; Schultz RM; Considine EL; Faul MM; Sullivan KA; Kolis SP; Carr MA; Zhang F
Bioorg Med Chem Lett; 2004 Aug; 14(15):3925-8. PubMed ID: 15225699
[TBL] [Abstract][Full Text] [Related]
2. Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles.
Wood ER; Kuyper L; Petrov KG; Hunter RN; Harris PA; Lackey K
Bioorg Med Chem Lett; 2004 Feb; 14(4):953-7. PubMed ID: 15013000
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of 1,7-annulated indoles and their applications in the studies of cyclin dependent kinase inhibitors.
Zhu G; Conner SE; Zhou X; Chan HK; Shih C; Engler TA; Al-Awar RS; Brooks HB; Watkins SA; Spencer CD; Schultz RM; Dempsey JA; Considine EL; Patel BR; Ogg CA; Vasudevan V; Lytle ML
Bioorg Med Chem Lett; 2004 Jun; 14(12):3057-61. PubMed ID: 15149644
[TBL] [Abstract][Full Text] [Related]
4. 1,7-annulated indolocarbazoles as cyclin-dependent kinase inhibitors.
Al-awar RS; Ray JE; Hecker KA; Huang J; Waid PP; Shih C; Brooks HB; Spencer CD; Watkins SA; Patel BR; Stamm NB; Ogg CA; Schultz RM; Considine EL; Faul MM; Sullivan KA; Kolis SP; Grutsch JL; Joseph S
Bioorg Med Chem Lett; 2004 Jun; 14(12):3217-20. PubMed ID: 15149678
[TBL] [Abstract][Full Text] [Related]
5. A new series of potent oxindole inhibitors of CDK2.
Luk KC; Simcox ME; Schutt A; Rowan K; Thompson T; Chen Y; Kammlott U; DePinto W; Dunten P; Dermatakis A
Bioorg Med Chem Lett; 2004 Feb; 14(4):913-7. PubMed ID: 15012993
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design and optimization of potent renin inhibitors on 5- or 7-azaindole-scaffolds.
Matter H; Scheiper B; Steinhagen H; Böcskei Z; Fleury V; McCort G
Bioorg Med Chem Lett; 2011 Sep; 21(18):5487-92. PubMed ID: 21840215
[TBL] [Abstract][Full Text] [Related]
7. Novel 5-azaindole factor VIIa inhibitors.
Riggs JR; Hu H; Kolesnikov A; Leahy EM; Wesson KE; Shrader WD; Vijaykumar D; Wahl TA; Tong Z; Sprengeler PA; Green MJ; Yu C; Katz BA; Sanford E; Nguyen M; Cabuslay R; Young WB
Bioorg Med Chem Lett; 2006 Jun; 16(12):3197-200. PubMed ID: 16621549
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of novel 5-substituted indirubins as protein kinases inhibitors.
Beauchard A; Ferandin Y; Frère S; Lozach O; Blairvacq M; Meijer L; Thiéry V; Besson T
Bioorg Med Chem; 2006 Sep; 14(18):6434-43. PubMed ID: 16759872
[TBL] [Abstract][Full Text] [Related]
9. Aza-stilbenes as potent and selective c-RAF inhibitors.
McDonald O; Lackey K; Davis-Ward R; Wood E; Samano V; Maloney P; Deanda F; Hunter R
Bioorg Med Chem Lett; 2006 Oct; 16(20):5378-83. PubMed ID: 16890436
[TBL] [Abstract][Full Text] [Related]
10. Benzodipyrazoles: a new class of potent CDK2 inhibitors.
D'Alessio R; Bargiotti A; Metz S; Brasca MG; Cameron A; Ermoli A; Marsiglio A; Polucci P; Roletto F; Tibolla M; Vazquez ML; Vulpetti A; Pevarello P
Bioorg Med Chem Lett; 2005 Mar; 15(5):1315-9. PubMed ID: 15713378
[TBL] [Abstract][Full Text] [Related]
11. Structure-based drug design of a highly potent CDK1,2,4,6 inhibitor with novel macrocyclic quinoxalin-2-one structure.
Kawanishi N; Sugimoto T; Shibata J; Nakamura K; Masutani K; Ikuta M; Hirai H
Bioorg Med Chem Lett; 2006 Oct; 16(19):5122-6. PubMed ID: 16876403
[TBL] [Abstract][Full Text] [Related]
12. Imidazo[2,1 -b]thiazolylmethylene- and indolylmethylene-2-indolinones: a new class of cyclin-dependent kinase inhibitors. Design, synthesis, and CDK1/cyclin B inhibition.
Andreani A; Cavalli A; Granaiola M; Leoni A; Locatelli A; Morigi R; Rambaldi M; Recanatini M; Garnier M; Meijer L
Anticancer Drug Des; 2000 Dec; 15(6):447-52. PubMed ID: 11716438
[TBL] [Abstract][Full Text] [Related]
13. 3D QSAR studies on GSK-3 inhibition by aloisines.
Zeng M; Jiang Y; Zhang B; Zheng K; Zhang N; Yu Q
Bioorg Med Chem Lett; 2005 Jan; 15(2):395-9. PubMed ID: 15603961
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of 2-amino-4-(7-azaindol-3-yl)pyrimidines as cyclin dependent kinase 1 (CDK1) inhibitors.
Huang S; Li R; Connolly PJ; Emanuel S; Middleton SA
Bioorg Med Chem Lett; 2006 Sep; 16(18):4818-21. PubMed ID: 16870444
[TBL] [Abstract][Full Text] [Related]
15. Janus kinase 2 inhibitors. Synthesis and characterization of a novel polycyclic azaindole.
Wang T; Duffy JP; Wang J; Halas S; Salituro FG; Pierce AC; Zuccola HJ; Black JR; Hogan JK; Jepson S; Shlyakter D; Mahajan S; Gu Y; Hoock T; Wood M; Furey BF; Frantz JD; Dauffenbach LM; Germann UA; Fan B; Namchuk M; Bennani YL; Ledeboer MW
J Med Chem; 2009 Dec; 52(24):7938-41. PubMed ID: 20014869
[TBL] [Abstract][Full Text] [Related]
16. Novel pyrrolyllactone and pyrrolyllactam indolinones as potent cyclin-dependent kinase 2 inhibitors.
Li X; Huang P; Cui JJ; Zhang J; Tang C
Bioorg Med Chem Lett; 2003 Jun; 13(11):1939-42. PubMed ID: 12749903
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of potent oxindole CDK2 inhibitors.
Dermatakis A; Luk KC; DePinto W
Bioorg Med Chem; 2003 Apr; 11(8):1873-81. PubMed ID: 12659774
[TBL] [Abstract][Full Text] [Related]
18. Ruthenium complexes as protein kinase inhibitors.
Zhang L; Carroll P; Meggers E
Org Lett; 2004 Feb; 6(4):521-3. PubMed ID: 14961613
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and structure-activity relationships of novel indirubin derivatives as potent anti-proliferative agents with CDK2 inhibitory activities.
Moon MJ; Lee SK; Lee JW; Song WK; Kim SW; Kim JI; Cho C; Choi SJ; Kim YC
Bioorg Med Chem; 2006 Jan; 14(1):237-46. PubMed ID: 16182537
[TBL] [Abstract][Full Text] [Related]
20. Novel 5-azaindolocarbazoles as cytotoxic agents and Chk1 inhibitors.
Lefoix M; Coudert G; Routier S; Pfeiffer B; Caignard DH; Hickman J; Pierré A; Golsteyn RM; Léonce S; Bossard C; Mérour JY
Bioorg Med Chem; 2008 May; 16(9):5303-21. PubMed ID: 18342518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
